Resolution

Gemeinsamer Bundesausschuss

of the Federal Joint Committee (G-BA) on an amendment of Pharmaceuticals Directive (AM-RL): Annex XII – Amendment of Information on the Period of Validity of a Resolution on the Benefit Assessment of Medicinal Products with New Active Ingredients According to Section 35a SGB V Cabozantinib

From 6 June 2019

At its meeting on 6 June 2019, the Federal Joint Committee (G-BA) resolved to amend the Directive on the Prescription of Medicinal Products in SHI-accredited Medical Care (Pharmaceuticals Directive) in the version dated 18 December 2008/22 January 2009 (BAnz. No. 49a of 31 March 2009), as last amended on TT. Monat JJJJ (BAnz AT TT.MM.JJJJ BX), as follows:

I. In Annex XII, the provision under II.2. concerning the period of validity of the resolution on the benefit assessment of Cabozantinib of 22 January 2015 shall be amended as follows:

The statement "1 January 2020", which entered into force with the resolution of 18 January 2018, shall be replaced by "1 November 2020".

II. The resolution will enter into force on the day of its publication on the internet on the website of the G-BA on 6 June 2019.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 06 June 2019

Federal Joint Committee
in accordance with Section 91 SGB V
Chair

Prof Hecken